Vaccination using well-characterized allogeneic tumor cell lines expressing standardized doses of immunostimulatory cytokines is an attractive alternative for autologous gene-transfected tumor cell vaccines. In the present study, we show that vaccination with irradiated allogeneic K1735 (H-2 k ) or B16F10 (H-2 b ) melanoma cells induces a moderate degree of cross-protection against the M-3 melanoma (H-2 d ) in DBA/2 mice. Cross-protection against the syngeneic tumor was markedly improved when the allogeneic vaccines were transfected with the interleukin-2 (IL-2) gene. The IL-2 gene-modified allogeneic vaccines were effective for prophylactic vaccination against subsequent tumor challenge and for therapeutic vaccination against pre-existing tumor deposits, with efficacies that were comparable with that of the IL-2 gene-modified syngeneic vaccines. Cross-protection correlated with the cytotoxic activity of splenocytes against M-3 targets. Allogeneic vaccination was not effective in another model, against the B16F10 melanoma in C57BL/6 mice, irrespective of genetic modification with the IL-2 or granulocyte-macrophage colony-stimulating factor genes. Cancer Gene Therapy (2000) 7, 870 -878
S
yngeneic murine tumor models have demonstrated the potency of cytokine gene-modified tumor cells to induce a systemic immune response, resulting in protection against subsequent tumor challenge and, in some cases, in the eradication of established tumors. [1] [2] [3] [4] [5] These preclinical animal studies have led to the initiation of numerous clinical trials. 6 -8 However, clinical trials using autologous gene-modified tumor cells have encountered major technical difficulties in expanding primary tumor cells to the numbers required for vaccination within the critical time frame dictated by the progression of the disease. 8, 9 Another major problem is the high variability in the transgene expression between tumor cells of different patients. 8, 10 These limitations make the autologous vaccination approach impracticable for broad clinical use, calling for technically more feasible alternatives. A local sustained release of cytokines at the vaccination site has been found to be crucial for the induction of a systemic antitumoral immune response. 11 Based on these findings, the use of sustained cytokine release systems such as microspheres, 12 liposomes, 13, 14 or cytokine gene-modified bystander cells 15 has been proposed as an alternative to autologous gene-modified tumor vaccines. However, these approaches still require sufficient amounts of each patient's own tumor cells.
An attractive alternative approach is to apply standardized gene-modified tumor cell lines as allogeneic vaccines to a broad variety of patients. This strategy is based on the findings that (a) a number of tumor antigens (Ags) are shared between different tumors, 16 -18 and (b) priming of CD4 ϩ and CD8 ϩ T cells occurs most probably mainly via professional Ag-presenting cells (APCs) of the host ("indirect priming") rather than by the tumor cells themselves ("direct priming"), making major histocompatibility complex (MHC) matching between vaccinating tumor cells and the recipient unnecessary. 11, 19, 20 Furthermore, recent studies have shown that expression of an allogeneic MHC molecule 21, 22 or admixing of allogeneic granulocyte-macrophage colonystimulating factor (GM-CSF) gene-modified bystander cells to a syngeneic vaccine 22 does not inhibit the induction of the antitumoral response but even can improve it, supporting the concept of allogeneic vaccination. Potential advantages offered by the allogeneic approach have led to a variety of clinical studies in which cytokine gene-modified, allogeneic melanoma cell lines are used. However, the conditions for functioning of a completely human histocompatibility leukocyte Ag-mismatched allogeneic vaccine have not been solidified yet, and thus the presence of at least one matched human histocompatibility leukocyte Ag class I allele that potentially presents peptide(s) derived from the tumor Ag has generally been preferred. 9, [23] [24] [25] Direct experimental or clinical data showing cross-protection against the syngeneic tumor conferred by a completely allogeneic vaccine are rather sparse. Toes et al 26 showed protection in a model in which both syngeneic tumor cells and allogeneic vaccines were engineered to express the adenoviral E1B epitope. Knight et al 27 found some cross-protection against the B16F10 melanoma induced by allogeneic vaccines. Most recently, they found that the antitumoral activity was enhanced by modification of the cells with the GM-CSF gene. 28 In the present study, we show that in the M-3 melanoma model, the cross-protection induced by allogeneic vaccines can be markedly enhanced by modification of the allogeneic vaccine with the interleukin-2 (IL-2) gene, resulting in cross-protection with an efficacy similar to the syngeneic IL-2 gene-modified vaccine. 
MATERIALS AND METHODS

Cells and media
Plasmids
The plasmid pWS2 coding for murine IL-2 (mIL-2) was used to transfect murine tumor cells. Plasmids were purified by column chromatography as described previously. 5 The lipopolysaccharide content of plasmids was measured by the Limulus amebocyte lysate assay (BioWhittaker, Walkersville, Md) and was Ͻ0.02 endotoxin units/g DNA.
Preparation of tumor cells used for vaccination
melanoma cells were transfected with the pWS2 plasmid by means of the adenovirus-enhanced transferrinfection (AVET) system as described previously. 5 The transfected cells were irradiated (25 Gy for M-3 cells; 50 Gy for K1735 or B16F10 cells) to prevent proliferation of the cells, harvested, washed, counted, frozen in vials, and stored in liquid nitrogen. The amount of mIL-2 produced by the cells was measured by thawing one of the vials, growing the cells for 24 hours, and determining the amount of mIL-2 in the cell culture supernatant by a mIL-2 enzyme-linked immunosorbent assay (Becton Dickinson, Bedford, Mass). Before vaccination, cryoconserved vaccines were thawed, taken up in complete medium, washed three times in Ringer's solution, and adjusted to the cell density required.
Prophylactic vaccination model
Two murine melanoma models in two different mouse strains were used.
In the first tumor model, Differences in the development of tumors between different vaccination groups were statistically analyzed using the logrank test (using GraphPad Prism software; GraphPad Software Inc., San Diego, Calif).
Therapeutic vaccination model
DBA/2 mice (8 weeks old; Bomholtgård) were injected s.c. with 5 ϫ 10 3 wild-type (wt) M-3 cells. After 5 days, mice were immunized three times at weekly intervals with 1 ϫ 10 6 IL-2 transfected or nontransfected M-3 or K1735 cells contralateral to the tumor implantation site; tumor development was monitored for 90 days after tumor cell inoculation. Differences in the development of tumors between different vaccination groups were statistically analyzed using the log-rank test (using GraphPad Prism software).
Assays for cytotoxic activity
Splenocytes of immunized mice (four mice per group) or NaCl-treated control mice were isolated 12 days after the last vaccination and restimulated for 5 days with paraformaldehyde-fixed stimulator cells (cells similar to those used for target cells) in normal culture medium (RPMI 1640, 10% FCS, 2 mM L-glutamine, 1 g/mL gentamycin) supplemented with 15 U/mL recombinant mIL-2. Cytolytic activity was determined by using a Europium (Eu 3ϩ ) release assay as described previously. 5 Cytolytic activity was measured (in triplicate) after a 2-hour incubation period of the restimulated splenocytes (effectors) with viable Eu 3ϩ -labeled target cells. Specific lysis was determined using the following formula: % specific lysis ϭ (experimental Eu 3ϩ release Ϫ spontaneous Eu 3ϩ release)/ (maximal Eu 3ϩ release Ϫ spontaneous Eu 3ϩ release). Spontaneous release was 10% for M-3, B16, and K1735 cells and Ͻ20% for YAC-1 and P815 cells of the maximum release induced by 1% Triton X-100. ). At 1 week after the second vaccination, mice were challenged with a 100-fold tumorigenic dose of wt M-3 cells. In addition, one group of nonvaccinated animals was challenged with the same tumor cell dose. After 3 weeks, all nonvaccinated animals developed a tumor. Vaccinated animals showed a moderate but significant delay in tumor growth, with some animals remaining tumor-free (P Ͻ .05 versus control) ( Fig 1A) . The protection induced by the allogeneic K1735 or B16F10 vaccines was slightly better when compared with that obtained with the syngeneic vaccine. A similar tendency was also found when the number of vaccinating cells was increased up to 2 ϫ 10 6 cells, resulting in four of eight or three of eight animals protected after vaccination with the allogeneic B16F10 or K1735 cells, respectively, compared with two of eight protected animals after vaccination with syngeneic M-3 cells (data not shown).
RESULTS
Allogeneic vaccines can induce immune responses against syngeneic M-3 melanoma
To test the underlying mechanism for this crossprotection, the splenocytes of immunized mice were analyzed for cytotoxic activity against allogeneic vaccine cells (i.e., K1735 and B16F10) and syngeneic M-3 tumor cells 12 days after the second vaccination. Animals vaccinated with the allogeneic B16F10 cells showed strong cytotoxic activity against B16F10 cells (Fig 1B) , and K1735-vaccinated animals showed moderate cytotoxic activity against K1735 cells (Fig 1C) . All vaccinated groups displayed significant cytotoxic activity against the syngeneic M-3 tumor (Fig 1D) . Notably, higher cytotoxic activity was found in the . A, At 1 week after the second vaccination, the mice were challenged with 3 ϫ 10 5 wt M-3 cells. As a control, one group of nonvaccinated animals was challenged with the same tumor cell dose. Tumor growth was monitored for 10 weeks. Differences in the development of tumors between different vaccination groups were statistically analyzed using the log-rank test. B-D, Cytolytic activity of splenocytes of immunized mice. Splenocytes of immunized mice (four mice per group) or NaCl-treated control mice were isolated and restimulated in vitro for 5 days. Cytolytic activity against the allogeneic vaccines (B,C) or against the syngeneic M-3 melanoma (D) was determined by using a Eu 3ϩ release assay. The mean Ϯ SEM of triplicates is shown.
allovaccinated animals than in animals vaccinated with the syngeneic vaccine.
Cross-protection against the syngeneic tumor is enhanced by IL-2 gene transfection Previous studies using syngeneic vaccination models have shown that transfection of the tumor cells with the IL-2 gene enhances antitumoral immune responses.
1,2,4,5
Syngeneic M-3 and allogeneic K1735 or B16F10 cells were transfected with the mIL-2 gene by means of the adenovirus-enhanced transferrinfection method. 5 The IL-2 gene-transfected cells were diluted with nontransfected irradiated cells to obtain a final IL-2 secretion of 100 -300 ng mIL-2/10 6 cells/24 hours, which has been found to result in maximal protection with syngeneic vaccines.
5 DBA/2 mice were vaccinated either with IL-2 gene-transfected irradiated allogeneic B16F10 or allogeneic K1735 cells, with IL-2 gene-transfected irradiated syngeneic M-3 cells, or with the respective nontransfected, irradiated cells. After two vaccinations, mice were challenged with wt M-3 cells. Allogeneic vaccines composed of nontransfected irradiated B16F10 or K1735 cells showed cross-protection against challenge with syngeneic M-3 melanoma cells in 25-30% of the animals (P Ͻ .01 versus untreated control, log-rank test). Cross-protection by the allogeneic vaccines was higher than the protection induced by syngeneic irradiated M-3 cells. Transfection with the IL-2 gene resulted in a dramatic increase in the efficacy of the syngeneic M-3 vaccines (P Ͻ .01, IL-2/M-3 versus M-3, log-rank test) and of the allogeneic K1735 vaccines (P Ͻ .01, IL-2/ K1735 versus K1735, log-rank test) and in a moderate increase in the efficacy of the B16F10 vaccine (Fig 2A) .
Splenocytes of syngeneic M-3 or allogeneic K1735 immunized mice were analyzed for alloreactivity against K1735 cells, cross-reactivity against the syngeneic M-3 tumor cells or against the unrelated syngeneic mastocytoma P815 tumor, and against YAC-1 cells to assess natural killer (NK) activity. K1735 vaccinated animals showed a moderate cytotoxic activity against the allogeneic K1735 cells (Fig 2B) that was markedly increased by IL-2 gene transfection. No alloreactivity against K1735 cells was found in M-3 vaccinated animals irrespective whether or not the vaccine cells were gene-modified.
Significant cytotoxic activity against M-3 cells was found in animals vaccinated with IL-2 gene-modified syngeneic M-3 cells and in animals vaccinated with IL-2 gene-modified allogeneic K1735 cells (Fig 2C) . In comparison, the nontransfected vaccines induced rather marginal activity. None of the vaccinated animals showed cytotoxic activity against the syngeneic, unrelated P815 mastocytoma (Fig 2D) . Cytotoxic activity against the NK target YAC-1 was found only in animals vaccinated with IL-2 gene-modified allogeneic K1735 vaccines (Fig 2E) . To minimize the contribution of NK activity to the measured cytotoxic activities against K1735 or M-3 cells in the IL-2/K1735 vaccinated animals, cytotoxic assays were also performed in the presence of a 10-fold excess of nonlabeled YAC-1 cells. The results indicate that NK activity is partially involved in the alloreactivity against K1735 cells (Fig 2B) , but does not seem to account for the cross-protection against syngeneic M-3 cells induced by vaccination with IL-2-transfected allogeneic K1735 cells (Fig 2C) .
Efficiency in therapeutic vaccination model
To test the efficiency of IL-2 gene-modified allogeneic vaccines in a therapeutic model, animals were injected with a tumorigenic M-3 cell dose 5 days before the start of treatment, simulating established s.c. micrometastases. Animals were vaccinated contralateral to the tumor site three times in weekly intervals with IL-2/K1735 cells, with IL-2/M-3 cells, with irradiated K1735 or M-3 cells, or, for comparison, with liposomes containing 300 ng of IL-2 (without tumor cells). The results showed a complete protection of the animals vaccinated with IL-2 gene-modified K1735 or M-3 cells (Fig 3) (P Ͻ .01 versus control, log-rank test). There was a lower but still significant protection of animals vaccinated with nontransfected K1735 cells (P Ͻ .05 versus control, log-rank test).
To rule out the possibility of a direct (systemic) effect of the IL-2 on the tumor, one control group was injected with IL-2-containing liposomes (without tumor cells) releasing doses of IL-2 that were similar to those secreted by the IL-2 gene-modified cells. Although the mixture of IL-2 liposomes and irradiated cells has been shown to be equally as effective as IL-2 gene-modified cells, 13, 14 IL-2 liposomes alone did not show any protection, indicating that the presence of both tumor Ag(s) and IL-2 is necessary for protection.
Lack of cross-protection of allogeneic vaccination against B16F10 melanoma
To test whether allogeneic vaccines can induce crossprotection against the B16F10 melanoma (H-2 b ), C57BL/6 mice were immunized with IL-2 gene-modified allogeneic M-3 (H-2 d ) or allogeneic K1735 cells (H-2 k ), with IL-2 gene-modified syngeneic B16F10 cells, or with the respective nontransfected irradiated cells. After two vaccinations, mice were challenged with a Ͼ100-fold tumorigenic dose of wt B16F10 cells. A group of nonvaccinated animals was also challenged. After 2 weeks, all nonvaccinated animals developed a tumor (Fig 4) . Significant protection was found in animals immunized with the syngeneic IL-2 gene-modified B16F10 cells, with six of ten animals being protected. Two of these six protected animals developed vitiligo at the tumor challenge site, whereas none of the nonprotected animals developed vitiligo. There was, however, no significant crossprotection found against B16F10 challenge with any of the allogeneic vaccines irrespective of IL-2 gene-modification.
To test whether the failure to induce cross-protection against the B16F10 melanoma by allogeneic vaccines is specifically related to the use of the IL-2 gene, similar experiments were performed using GM-CSF gene-modified allogeneic vaccines. Also in this case, no significant ). Expression of IL-2 was in 100 -300 ng per 24 hours in all cases. For comparison, animals were vaccinated either with 1 ϫ 10 6 nontransfected, irradiated allogeneic B16F10 or K1735 cells or with nontransfected, irradiated syngeneic M-3 cells. A, At 1 week after the second vaccination, mice were challenged with 3 ϫ 10 5 wt M-3 cells. As a control, one group of nonvaccinated animals was challenged with the same tumor cell dose. Tumor growth was monitored for 8 weeks. Numbers of protected animals are shown. Differences in the development of tumors between different vaccination groups were statistically analyzed using the log-rank test. B-E, Cytotoxic activity of splenocytes of immunized mice. Splenocytes were isolated (from four mice per group) and restimulated in vitro for 5 days. Cytolytic activity against the allogeneic K1735 vaccines (B), the syngeneic M-3 melanoma (C), the unrelated P815 tumor (D), or YAC-1 cells (E) was determined by using a Eu 3ϩ release assay. Data (mean Ϯ SEM) of three independent experiments (each measured in triplicate) are presented.
cross-protection was found with allogeneic vaccines, whereas syngeneic GM-CSF gene-modified vaccines induced significant protection (data not shown).
DISCUSSION
Vaccination with tumor cells genetically engineered to produce immunostimulatory cytokines has become an promising strategy to enhance antitumoral immune responses. However, the translation of this strategy to large-scale human therapy is critically limited by the highly individual nature of the autologous vaccination approach. This has turned the general interest toward a more generic allogeneic vaccination. Unfortunately, animal models of allogeneic vaccination protocols are seriously limited mainly due to the fact that in contrast to human tumors, Ag sharing between different established animal tumor cell lines appears to be rare (reviewed in Ref. 9) , although examples of Ag sharing have been described previously. 18 Due to the lack of allogeneic vaccination models in mice, specific aspects of allogeneic vaccination have been assessed mainly in mixed allogeneic/syngeneic models in which either allogeneic MHC molecules were introduced into syngeneic tumors 21, 22 or allogeneic cells were admixed to syngeneic , or the respective nonmodified irradiated cells. At 1 week after the second vaccination, mice were challenged with 1 ϫ 10 5 wt B16F10 cells. As control, one group of nonvaccinated animals was challenged with the same tumor cell dose. Tumor growth was monitored for 10 weeks. Differences in the development of tumors between different vaccination groups were statistically analyzed using the log-rank test.
tumor cells. 15, 22 There has been one model described in which vaccines derived from completely allogeneic tumors carrying only the natural tumor Ags induced cross-priming against the syngeneic tumor. Knight et al 27 showed that vaccination of C57BL/6 mice (H-2 b ) with irradiated allogeneic K1735-M2 cells (H-2 k ) induced some level of cross-protection against syngeneic B16 cells. Cross-protection was enhanced by transfection of the cells with the GM-CSF gene. 28 IL-2 is another cytokine that has been proven to be effective in syngeneic tumor vaccination.
1,2,4,5 IL-2, in addition to its role in the activation and maturation of T lymphocytes, is known to stimulate NK cells, lymphokine-activated killer precursors, and macrophages, which express primarily an intermediate-affinity IL-2 receptor and thus require higher IL-2 concentrations. In syngeneic vaccination models, it has been shown that an increased attraction and activation of inflammatory cells at the vaccination site can result in more efficient tumor Ag uptake, processing, and presentation by the host's APCs, resulting in the induction of cytotoxic T-lymphocyte (CTL) activity against the parental tumor. 19, 20 In the present study, we show that vaccination with IL-2 gene-modified cells derived from two allogeneic tumors can induce therapeutically significant systemic immune responses against the syngeneic tumor with similar efficacy compared with the syngeneic vaccine. Expression of the immunostimulatory cytokine IL-2 by the immunizing cells is necessary for efficient protection. The increased CTL activity after immunization with IL-2 gene-modified allogeneic tumor cells indicates mechanisms for allogeneic vaccination that are similar to those for the syngeneic vaccines. 19, 20 The data of the M-3 model show a good correlation between cytotoxic activity and protection from tumor challenge.
Although there was significant cross-protection in DBA/2 mice against the syngeneic M-3 tumor (H-2 ) with the allogeneic M-3 or allogeneic K1735 cells did not lead to significant cross-protection against B16 challenge irrespective of IL-2 expression. In contrast, syngeneic B16 cells expressing similar amounts of IL-2 as the allovaccines protected 60% of the animals against B16 wt challenge. In this model, there was also no cross-protection by allogeneic vaccines modified with the GM-CSF gene (data not shown). These findings indicate that the cross-protection induced by allogeneic cells has to fulfill certain premises to function properly. When comparing the M3/DBA/2 versus the B16F10/C57BL/6 models, a number of factors appear to be decisive for the outcome of the vaccination:
Importance of shared Ags. The allogeneic vaccine must contain tumor Ags that are relevant for the host. Unfortunately, in contrast to human melanoma, the current knowledge of mouse melanoma-derived tumor Ags is limited to a small number. The induction of vitiligo after vaccination indicates that immune reactions against Ags shared by melanoma cells and normal melanocytes such as Trp-1, Trp-2, gp100, and tyrosinase may be involved.
29, 30 However, their significance in tumor rejection still remains to be established. Nevertheless, we did not find cross-protection against the B16 melanoma after vaccination with allogeneic K1735 cells irrespective of modification with the genes for IL-2 or GM-CSF, whereas cross-protection between K1735-M2 and B16 has been reported by Knight et al. 27 This difference may be due to the fact that different sublines of the K1735 cells were used in the two studies, and K1735 sublines are known to differ greatly in morphology and growth behavior; additional differences in Ag and MHC expression between the sublines can be assumed. Contribution of CTL-independent pathways to tumor rejection. Although protection against the B16 melanoma repeatedly has been shown after immunization with irradiated B16 cells expressing immunostimulatory cytokines such as GM-CSF or IL-2, 3,5,22 the underlying effector mechanisms are complex and not fully understood. Although CTLs against B16 are more difficult to generate even under conditions in which rejection is induced, 3, 5, 13 other mechanisms such as NK cells and antibody-mediated killing may play a major role. The development of vitiligo at vaccination and/or tumor challenge sites (Ref. 13 and the present study) seems to support this notion, because antibody-mediated mechanisms are known to play a crucial role in vitiligo. 29, 30 In contrast, vaccination-induced protection against the M-3 melanoma correlates with strong CTL activity against M-3 targets. 5 Thus, one has to consider that induction of non-CTL pathways in an allogeneic setting can differ from those in the syngeneic setting.
Therapeutic efficacy of vaccination may be influenced by the tumor characteristics. The B16F10 melanoma represents a more aggressively growing tumor compared with the M-3 melanoma. It is certainly more difficult to induce significant protection against aggressively growing tumors.
In conclusion, the present study demonstrates that allogeneic vaccination can induce cross-protection against a syngeneic tumor with an efficacy that is com-parable with syngeneic vaccines, providing additional support for the hypothesis that MHC matching is not required. Release of immunostimulatory cytokines at the vaccination site is necessary for efficient protection, both for syngeneic and for allogeneic vaccination. The data also indicate that in certain cases, allogeneic vaccination may be less effective than syngeneic vaccination. Although we do not completely understand all parameters, the data indicate that efficacy of allogeneic vaccination will depend not only upon maximal sharing of relevant tumor rejection Ags between the vaccinating cells and the recipient but also on the characteristics of the patient's tumor. The differences in the efficacies of allogeneic vaccination found in the two different tumor models may reflect the spectrum that has to be expected in the human situation. Although animal studies such as the present study can demonstrate the principle possibility that IL-2 gene-modified allogeneic vaccination can induce a significant cross-protection, final answers on therapeutic efficiency have to be given by clinical trials.
